Duloxetine Capsule, Delayed Release
Product Images NDC 60760-759

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 60760-759). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

6076-759 (Duloxetine 60760 759 30)

Label for Duloxetine Delayed-Release Capsules 20 mg, quantity 30, manufactured by Ajanta Pharma USA Inc., made in India. Packaged by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. The label includes dosage form, strength, NDC 60760-759-30, and storage instructions to keep at controlled room temperature 15°-30°C (59°-86°F).*

FDA Label Image

Figure1 (Duloxetine Fig1)

A Kaplan-Meier survival curve chart comparing the proportion of patients with relapse over time from randomization to relapse in days. The chart includes two treatment groups: placebo and duloxetine. The vertical axis indicates the proportion of patients with relapse, ranging from 0 to 1, while the horizontal axis shows time in days up to 250.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph comparing the percentage of patients improved versus the percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The graph shows two curves indicating higher patient improvement percentages for Duloxetine compared to placebo across various pain improvement thresholds from >0 to 100.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A Kaplan-Meier survival curve chart comparing the proportion of patients with relapse over time (days) from randomization, for two treatments: Placebo and Duloxetine. The x-axis represents time in days, and the y-axis shows the proportion of patients with relapse, ranging from 0 to 1. The chart visually indicates fewer relapses over time in patients treated with Duloxetine compared to Placebo.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo, with lines indicating patient improvement trends across increasing pain improvement percentages.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline for three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. The x-axis represents percent improvement from 0 to 100%, while the y-axis shows the percentage of patients improved, declining as percent improvement increases.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph illustrating the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60mg taken twice daily, Duloxetine 60mg once daily, and placebo groups, showing patient improvement trends across varying pain relief percentages.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph comparing percent improvement in pain from baseline on the x-axis with percentage of patients improved on the y-axis for Duloxetine at 20 mg, 60 mg, and 120 mg once daily doses versus placebo. The graph shows higher improvement percentages for all Duloxetine doses compared to placebo.*

FDA Label Image

Figure7 (Duloxetine Fig7)

A line graph comparing percent improvement in pain from baseline versus percentage of patients improved. It shows two lines representing 'Duloxetine 60 mg Once Daily' and 'Placebo'. The x-axis is labeled 'Percent improvement in Pain from Baseline' and the y-axis is labeled 'Percentage of Patients Improved' with values from 0 to 100.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved by percent improvement in pain from baseline, using the Last Observation Carried Forward (BOCF) method, for a placebo group versus a Duloxetine 60/120 mg once daily group. The x-axis shows percent improvement in pain from 0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100 percent. Two lines represent the placebo (dotted with x marks) and Duloxetine treatment (solid with diamond marks).*

FDA Label Image

Figure9 (Duloxetine Fig9)

Line graph depicting the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares Placebo to Duloxetine 60 mg once daily, showing higher improvement rates generally for Duloxetine across various pain improvement percentages.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure of duloxetine hydrochloride showing a naphthyl group, thiophene ring, and an amine group with a hydrochloride moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.